Compare FNB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNB | LEGN |
|---|---|---|
| Founded | 1864 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.9B |
| IPO Year | 2001 | 2020 |
| Metric | FNB | LEGN |
|---|---|---|
| Price | $15.85 | $18.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $19.10 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 7.0M | 1.7M |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | ★ 22.83 | N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.53 | $46.27 |
| Revenue Next Year | $7.90 | $28.77 |
| P/E Ratio | $10.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.93 | $16.24 |
| 52 Week High | $19.14 | $45.30 |
| Indicator | FNB | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 28.46 | 49.02 |
| Support Level | $15.47 | $17.46 |
| Resistance Level | $16.38 | $23.68 |
| Average True Range (ATR) | 0.48 | 0.81 |
| MACD | -0.17 | 0.16 |
| Stochastic Oscillator | 1.88 | 47.10 |
F N B Corp provides a full range of financial services, principally to consumers, corporations, governments and small- to medium-sized businesses. It has three reportable business segments: Community Banking, Wealth Management and Insurance. The majority of revenue is from the Community banking segment. It offers commercial & consumer banking services. Commercial banking solutions include corporate banking, small business banking, investment real estate financing, business credit, capital markets & lease financing. Consumer banking products & services include deposit products, mortgage lending, & consumer lending & a complete suite of mobile & online banking services.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.